Gut Microbes: Systemic Disease. Mark Pimentel, MD. Cedars-Sinai Medical Center. Mark Pimentel, MD, FACG
|
|
- August Wiggins
- 6 years ago
- Views:
Transcription
1 Gut Microbes: Role in Health, IBS, GI and Systemic Disease Mark Pimentel, MD Director, GI Motility Program Cedars-Sinai Medical Center 1
2 Lacks cellulase cannot breakdown cellulose Depends completely on microbial flora to digest cellulose 50 billion bacteria per 1mm of rumen Anerobic enviroment Byproduct: Methane Kill ALL GI microbes Kill SOME GI microbes 2
3 Number of Cells 100x more Bacterial cells Bacterial Cells Human Cells Types of Cells Clostridium Lactobacillus Methanobrevibacter E.coli 500 different species Enterococcus 3
4 Types of Cells Clostridium Lactobacillus Methanobrevibacter E.coli 500 different species Enterococcus Micro-environments Air pocket Intestinal Wall Mucus Layer Oxygen/CO 2 / Nitrogen/H 2 Liquid Phase Anaerobic Solid Phase-Stool 4
5 SIBO- What is it? Duodenum Small Bowel ~ 0 cfu/ml Colon cfu/ml Cecum Jejunum Ileum 10 1 cfu/ml 10 2 cfu/ml 10 3 cfu/ml Breath Testing is abnormal in IBS Forest plot of all age-sex matched studies Type of % % Author Breath Test OR (95% CI) CI) Weight Weight Grover sucrose 2.29 (0.89, 5.87) 5.87) Lupascu Pimentel glucose lactulose (3.52, 33.71) 33.71) (5.29, 80.69) 80.69) Parodi glucose 4.30 (1.24, 14.98) 14.98) Scarpellini Collin lactulose lactulose l (7.35, 80.15) 80.15) (6.55, 49.71) 49.71) Overall (I-squared = 67.9%, p = 0.008) 9.64 (4.26, 21.82) 21.82) NOTE: Weights are from random effects analysis Shah, et al Dig Dis Sci,
6 Is Breath Testing Accurate? Orocecal Transit= 5% in cecum Tc + Lactulose ppm Issues -95% in small bowel -Time to peak fermentation -Is 0.5g of lactulose enough Yu, et al. Gut 2011 Is Breath Testing Accurate? 37ºC Hydrogen (ppm) Stool 0.5g Lactulose + PBS Winter, et al. ACG,
7 Is Breath Testing Accurate? 99Tc + Lactulose Orocecal Transit= 5% in cecum 60 minutes ppm Winter, et al. ACG 2012 Small Bowel Culture in IBS ercent of Subjects P P<0.05 P< % 24% 12% 4% >10,000 coliforms >5,000 coliforms Control IBS N=165 IBS, 26 controls Posserud, et al, Gut, 2007;56:
8 Mechanism: SIBO = IBS (Culture) ercent of Subjects % 60% P= Non- D-IBS D-IBS P 10 0 N=77 non-d-ibs, N=35 D-IBS Pyleris, et al. DDS, 2012 Mechanism: SIBO = IBS (qpcr) DUODENAL ASPIRATES 6 P<0.05 acteria quantity Log10 B P<0.05 Healthy Not-IBS IBS 0 E. coli Klebsiella N=77 non-d-ibs, N=35 D-IBS Pyleris, et al. UEGW,
9 Risk of PI-IBS Increases 7-fold After Infectious Gastroenteritis* Protective Effect Study (year/bacteria) Ji (2005/Shigella) Mearin (2005/Salmonella) Wang (2004/Unspecified) Okhuysen (2004/Unspecified) Cumberland (2003/Unspecified) llnyckyj (2003/Unspecified) Parry (2003/Bacterial NOS) Rodriguez (1999/Bacterial NOS) Pooled estimate t Increased Risk OR OR (95% Cl) 2.8 ( ) 8.7 ( ) 10.7 ( ) 10.1 ( ) 6.6 ( ) 2.7 ( ) 9.9 ( ) 11.3 ( ) 73( ( ) 1) 9.8% IBS in cases vs 1.2% IBS in controls *Systematic review of 8 studies involving 588,061 subjects; follow-up ranged from 3 to 12 months. Halvorsen HA et al. Am J Gastroenterol. 2006;101: Characteristics of Acute Illness Identify Patients at Risk for PI-IBS 10 P=.000 OR for IBS After Acute Gastroenteritis* P=.029 P=.006 P=.013 P=.001 P= Age Female Diarrhea >7 d Bloody Stools Abdominal Cramps Weight Loss >10 lbs *Identified from multiple logistic regression analysis from 2069 participating in the Walkerton Health Study. Marshall JK et al. Gastroenterology. 2006;131:
10 Salmonella and PI-IBS Percent with Relative Risk IBS at 1 year (CI) Irritable Bowel 12% 5.2 ( ) Non-ulcer dyspepsia 15% 7.8 ( ) Nausea was a risk factor for NUD Mearin, et al. Gastro, 2006 NORMAL ACUTE GASTROENTERITIS 90% 10% COMPLETE ~GENETIC SUSCEPTIBILIITY RECOVERY ~ABNORMAL HOST RESPONSE ~TOXIN INTENSITY FUNCTIONAL POST-INFECTIOUS GI DISEASES? IBS 10
11 Post-infectious IBS = IBS Shah, et al J Neurogastroenterol Motil, 2012 Mechanism: Rat Model (SIBO = IBS) n=33 n=33 C. jejuni Stool = Campy- No Acute Gastroenteritis Stool = Campy+ Acute Gastroenteritis 3 Months After Recovery Stool Consistency Evaluation Stool = Campy- Recovery Bacterial Quantitation by RT-PCR of Duodenum, Jejunum, Ileum Pimentel, et al. Dig Dis Sci,
12 Mechanism: Rat Model (SIBO = IBS) Percent of rats with SI IBO % 21% 17% 6.7% Duodenum Jejunum ileum Total 3 months after Campylobacter jejuni infection Pimentel, et al., Dig Dis Sci, 2008 ICC and CDT toxin C. jejuni E. Coli Salmonella Shigella Cytolethal Distending Toxin (CDT) All cause IBS A B Cell G2 Phase Unknown Entry Arrest 12
13 IBS Mechanism/CdtB causes IBS Campy CDT- P-value Rifaximin P-value Stool % wet weight 60.1± ± ± Consistency 1.51± ±0.27 < ±0.30 < Standard Deviation 8.4± ±2.4 < ±2.3 < Proportion with normal bowel form all 3 days 17.8% 50.0% <0.01 OR= % < OR=6.7 Note: No significant differences were seen between CDT- and Rifaximin treated arms of the study. Morales, et al. J Neurogastroenterl Motil, 2012 Pimentel, et al. Dig Dis Sci, 2011 IBS Mechanism/Nerve Damage CONTROLS 20x Jee, et al. World J Gastroenterol,
14 IBS Mechanism/Nerve Damage Campy with SIBO 20x Jee, et al. World J Gastroenterol, 2010 IBS Mechanism/Nerve Damage Campy no CdtB 20x Jee, et al. World J Gastroenterol,
15 IBS Mechanism/Autoimmune to Nerves RAT MODEL Pre-immune serum (CONTROL) wab (ANTI- CDTB) Rat Ganglia Rat ICC ckit + wab wab Anti-CdtB is Anti-Glial Anti-CdtB is anti-icc 15
16 IBS Mechanism/Nerve Damage GANGLIA OF HUMAN ILEAL SECTIONS wab S-100 S wab Anti-CdtB is also Anti-glial in humans IBS Mechanism/Sequence/Main Food Poisoning Bacterial Toxin Autoimmunity Gut Nerve Damage Bacterial Overgrowth IBS 16
17 Primary Outcome (4 weeks after Tx) Efficacy Outcome Study Primary SGA-IBS Weekly Odds Ratio (95% CI) p-value (1.10,2.12) (1.05,2.01) (1.18,1.88) Key Secondary IBS Bloating Weekly (1.16,2.27) (1.08,2.06) (1.23,1.96) Other Secondary SGA-IBS Daily IBS Bloating Daily IBS Ab Pain Daily (1.26,2.47) (1.13,2.24) (1.28,2.04) < (1.01,1.97) (1.26,2.44) (1.21,1.92) (1.05,2.02) (1.05,2.03) (1.13,1.78) FDA Proposed Ab Pain & Stool Daily (FDA) Ab Pain Daily (FDA) Stool Consist. Daily (FDA) (1.02,1.92) (1.12,2.13) (1.17,1.84) (1.08,2.03) (1.06,2.00) (1.17,1.83) (1.25,2.59) (1.12,2.21) (1.31,2.14) < Pimentel, et al NEJM, Odds Ratio and 95% CI Favors Placebo Favors Rifaximin Durability of Response (3 months) Efficacy Odds Study (95% CI) p-value Outcome Ratio 1.35 (1.00, 1.82) Primary SGA-IBS 1.52 (1.13, 2.03) Weekly 1.44 (1.17, 1.77) Key Secondary IBS Bloating Weekly (0.95, 1.73) (1.16, ) (1.15, 1.75) Other Secondary SGA-IBS Daily IBS Bloating Daily IBS Ab Pain Daily (1.18, 2.18) (1.09, 1.99) (1.20, 1.83) (1.10, 2.04) (1.24, 2.25) (1.24, 1.89) (1.00, 1.83) (1.01, 1.81) (1.06, 1.61) < FDA Proposed Ab Pain & Stool Daily (FDA) Ab Pain Daily (FDA) Stool Consist. Daily (FDA) (1.01, 1.83) (1.08, 1.92) (1.14, 1.72) (0.98, 1.75) (1.03, 1.83) (1.09, 1.64) (1.24, 2.33) (1.09, 2.00) (1.27, 1.97) < Odds Ratio and 95% CI Pimentel, et al NEJM, 2011 Favors Placebo Favors Rifaximin 17
18 Antibiotic Resistance Conventional Antibiotics Recurrence SIBO 40% Eradicated 25% Eradicated Rifaximin Recurrence 70% Eradicated 100% Eradicated Yang, et al. Dig Dis Sci, Harm with Drugs in IBS DRUG NNT NNH Benefit to Harm Desipramine Alosetron Rifaximini i NNT=Number needed to treat. NNH=Number needed to harm. NNH=number of subjects treated for one subject to withdraw due to an adverse event that was greater than the equivalent in placebo. Shah, et al. Am J Med,
19 Harm with Drugs in IBS Drug Desipramine Alosetron Rifaximin Excess of Placebo Only Dry mouth, flushing, constipation, insomnia, decreased appetite, palpitations Constipation, Abdominal pain/discomfort Bad Taste in mouth Shah, et al. Am J Med, in press. Compared to other Drugs +12.5% +13% +10% -16% -17% Net value -3.5% -4% +10% Shah, et al. DDW,
20 Retreatment with Rifaximin Percent of subjects who respo onded /40 17/18 54/65 6/7 3/4 1st RTX 2nd RTX 3rd RTX 4th RTX 5th RTX Pimentel, et al. Dig Dis Sci, Retreatment with Rifaximin before an number of months relapse Media N=63 Range= mo N=46 Range=1-45 months N=21 Range=2-37 mo N=6 Range=1-18 mo N=4 Range=2-24 mo 1st RTX 2nd RTX 3rd RTX 4th RTX 5th RTX Note: RTX is the retreatment number. In this figure, the time (in months) refers to the number of months of wellness before the treatment number in each column. For example, for 1 RTX, it would be the number of months the patient was well after the first rifaximin administration and prior to the 1 RTX. Note: Rare patients were missing accurate dates and thus were not included here. Note: The median is a more accurate depiction of the duration of benefit since the ranges were wide. Pimentel, et al. Dig Dis Sci,
21 Complexities of Gas Production Methane Hydrogen 70 Hydrogen Producers H 2 M illio n P a r t s P e r M Methane 10 Producers 0 4H 2 1CH Time (Minutes) 70 on Parts Per Milli Time (Minutes) H 2 H 2 S Producers 5H 2 1H 2 S P a rts P e r M illio n Time (Minutes) Methane- Important in C-IBS Meta-analysis of studies Author Year OR (95% (95% CI) CI) % % Weight Weight Peled 1987 Fiedorek 1990 Pimentel 2003 Pimentel 2003 Majewski 2007 Bratten 2008 Parodi 2009 Hwang 2009 Attaluri 2009 Overall (I-squared = 64.6%, p = 0.004) 0.83 (0.20, (0.20, 3.56) 3.56) 4.32 (1.60, (1.60, 11.68) 11.68) 5.58 (2.22, (2.22, 14.03) 14.03) (2.48, (2.48, ) ) 1.81 (0.70, (0.70, 4.67) 4.67) 2.22 (1.14, (1.14, 4.33) 4.33) 1.89 (0.79, (0.79, 4.51) 4.51) (8.73, (8.73, ) ) 3.70 (2.06, (2.06, 6.66) 6.66) 3.51 (2.00, (2.00, 6.16) 6.16) NOTE: Weights are from random effects analysis Kunkel, et al. Dig Dis Sci,
22 Methane as a diagnostic test C-IBS Not C-IBS Methane No Methane Sensitivity=0.92, Specificity=0.81, Positive Predictive Value=0.79, Negative Predictive Value=0.93 Pimentel, et al Dig Dis Sci Methanobrevibacter smithii- the cause of constipation Hydrogen Producing IBS Stool Methane Producing IBS Stool Kim, et al. DDW,
23 Methanobrevibacter smithii or methane as a test- dictates treatment Percen nt eradicating CH4 CH4 Eradication Clinical Response 100 P= P= Neomycin Rifaximin Neo+Rifax Percent with Clinical Response Neomycin Rifaximin Neo+Rifax Low, et al. Gastroenterol and Hepatol 2010 IBS/SIBO WORKSHEET 3.0 Molecular Mimicry Acute Gastroenteritis Immune response Anti-CDT Ab Other Ab React to neural elements/myenteritis Reduced DMP-ICC Immunity to Infection STRESS PROKINETIC SMALL BOWEL COLON CRF DYSMOTILITY METHANE SIBO/ IBS HYDROGEN SLOW TRANSIT C-IBS ANTIBIOTIC D- AND M-IBS 23
24 Lessons from the Germ Free Mouse Reduced organ weight Reduced cardiac output Reduced O2 consumption Increased food intake Reduced mediastinal and sympathetic lymph nodes Reduced mucosal associated lymphoid tissue Reduced serum immunoglobulins Tannaock, Am J Clin Nutrition 2001 Defense of Host by detecting and sampling Nutrients for Host Information for Host immune development IMMUNE REGULATION GUT FLORA DEFENSE AGAINST PATHOGENS NUTRITION/ METABOLISM 24
25 Specific Host Microbe Interaction Modulate Immune Response Modulate other Bacteria Impact Appetite Regulation Digest the Indigestible Vitamin Production and Metabolism Produce Peptide Mediators Gut Microbes Generate Heat and change BMR Gas Production and Effects Inflammatory Response Germ Free Animals Germ Free -Low body weight -Increased oral intake + = Add Fecal Flora Gain 60% more body weight with reduced oral intake Backhed F Proc Natl Acad Sci U S A Nov 2 101(44)
26 Fecal Transplant Germ Free -Low body weight -Increased oral intake + = Add Fecal Flora (Bacteroidetes>Firmicutes) Gain weight with reduced oral intake Germ Free -Low body weight -Increased oral intake + = Add Fecal Flora from Obese mice (Firmicutes>Bacteroidetes) Far greater weight gain Turnbaugh Nature 444, (21 December 2006) Energy lost in stool Bomb calorimetry of the fecal gross energy content (kcal g -1 )of lean (+/+) and obese (ob/ob) conventionally raised ( *P<0.05, ***P<0.001) In addition ob/ob cecal microbiota = increased Methanogenic archaea Turnbaugh Nature 444, (21 December 2006) 26
27 Methanogen Model No Methanobrevibacter smithii Indigestible Substrate H 2 Intoxicates self Methanobrevibacter smithii Indigestible Substrate H 2 H 2 H 2 H 2 CH 4 Energy Digestible Substrates ENERGY DIGESTIBLE SUBSTRATE = Syntroph = Methanogen Body Mass Index and PCOS Mathur R et al Digestive Disease Sciences. 55(4):1085,
28 Percent Body Fat and PCOS Mathur R, et al Digestive Disease Sciences. 55(4):1085, 2010 Methane in Obese Patients Mathur et al, Gastro and Hep,
29 Methane in Non-obese Patients BMI Multivariate analysis controlling for age, sex, diabetes, anti depressant and other confounding (P<0.001) Normal Breath test N=792 Positive Hydrogen Breath Test Only Methane Methane and Hydrogen Positive Mathur R, et al. JCEM in press 2013 Methane and Glucose Metabolism Glucose AUC (mg/dl) 800 n= No methane P=0.03 Methane 29
30 M smithii and Body Weight in New Animal Model Mathur R, et al. Obesity 2013 Conclusions The basis for IBS may be acute gastroenteritis and SIBO Antimicrobial therapies benefit IBS subjects Autoimmunity may play a role in IBS and gut microbe changes Bacteria are important in obesity Methanogens have a significant future role in constipation and metabolic syndrome 30
New Developments in Irritable Bowel Syndrome
New Developments in Irritable Bowel Syndrome Mark Pimentel, MD, FRCP(C) Director, GI Motility Program Cedars-Sinai Medical Center IBS Forks in the Road Not all decisions in how to handle IBS made things
More informationWilliam Chey, MD University of Michigan Ann Arbor, MI
Lin Chang, MD David Geffen School of Medicine at UCLA Los Angeles, CA William Chey, MD University of Michigan Ann Arbor, MI Mark Pimentel, MD Cedars-Sinai Medical Center Los Angeles, CA Accredited by Jointly
More informationIrritable Bowel Syndrome 4/11/2017. New Insights in Irritable Bowel Syndrome. Overview
70 60 50 40 30 20 10 0 0 15 30 45 60 75 90 105 120 135 150 165 180 Time (Minutes) 4/11/2017 New Insights in Irritable Bowel Syndrome Christopher Chang, MD, PhD Division of Gastroenterology/Hepatology University
More informationDrugs for Bugs: The Next Generation of Pharmaceuticals
Drugs for Bugs: The Next Generation of Pharmaceuticals Mark Pimentel, MD, FRCP(C) Executive Director, Medically Associated Science and Technology (MAST) Program Cedars-Sinai Medical Center Microbiome The
More informationSIBO
SIBO What is it? Small Intestinal Bowel Overgrowth A chronic bacterial infection of the small intestine Caused by bad bacteria such as E Coli and Clostridium migrating to the small intestine There is not
More informationMicrobiome GI Disorders
Microbiome GI Disorders Prof. Ram Dickman Neurogastroenterology Unit Rabin Medical Center Israel 1 Key Points Our gut microbiota Were to find them? Symbiosis or Why do we need them? Dysbiosis or when things
More informationPrimary Management of Irritable Bowel Syndrome
Primary Management of Irritable Bowel Syndrome Jasmine Zia, MD Acting Instructor, Division of Gastroenterology Current Concepts in Drug Therapy CME Course April 23, 2015 Irritable Bowel Syndrome (IBS)
More informationIRRITABLE BOWEL SYNDROME: ROLE OF GUT BACTERIA AND BACTERIAL TOXINS. CHRISTOPHER CHANG, GILLIAN BARLOW, STACY WEITSMAN, and MARK PIMENTEL
Old Herborn University Seminar Monograph 27: Persisting consequences of intestinal infection. Editors: Peter J. Heidt, Dennis Lang, Mark Riddle, Richard Walker, and Volker Rusch. Old Herborn University
More informationAPDW 2016 Poster No. a90312
APDW 2016 Poster No. a90312 SYN-010, a Proprietary Modified-Release Formulation of Lovastatin Lactone, Lowered Breath Methane and Improved Stool Frequency in Patients with IBS-C Results of a multi-center,
More information1. BACKGROUND. Lovastatin β-hydroxyacid No effect on methane production Inhibits cholesterol synthesis
1. BACKGRUND Methane production by the archeon Methanobrevibacter smithii (M. smithii) is a ubiquitous process in the intestine, disposing of hydrogen and other by-products formed during carbohydrate digestion
More informationNicholas J. Talley, MD University of Newcastle Callaghan, NSW Australia. Mark Pimentel, MD Cedars-Sinai Medical Center Los Angeles, CA
Lin Chang, MD David Geffen School of Medicine at UCLA Los Angeles, CA Mark Pimentel, MD Cedars-Sinai Medical Center Los Angeles, CA Nicholas J. Talley, MD University of Newcastle Callaghan, NSW Australia
More informationGut microbiota: importance
Gut microbiota: importance Gut microbiota: importance BACTERIA IN THE GUT SYNTHESIZE SEVERAL HUNDRED GRAMS OF ESSENTIAL AMINO-ACIDS EVERY DAY PROKARYOTES (Bacteria) capability to synthesize essential compounds
More informationNew Tests and Treatments for Dyspepsia and Irritable Bowel Syndrome
New Tests and Treatments for Dyspepsia and Irritable Bowel Syndrome Soojong Hong Chae, MD Clinical Assistant Professor Digestive Diseases and Nutrition University of South Florida ROME III Functional dyspepsia
More informationSmall Intestinal Bacterial Overgrowth. Lela Altman, ND, EAMP Adjunct Faculty and Clinical Supervisor at the Bastyr Center for Natural Health
Small Intestinal Bacterial Overgrowth Lela Altman, ND, EAMP Adjunct Faculty and Clinical Supervisor at the Bastyr Center for Natural Health Acknowledgements Special thanks to Eric Schoen (ND Candidate),
More informationIrritable bowel syndrome (IBS) is a functional gastrointestinal. Bacteria and the Role of Antibiotics in Irritable Bowel Syndrome INTRODUCTION
Bacteria and the Role of Antibiotics in Irritable Bowel Syndrome by Mark Pimentel Although several pathophysiologic models have been suggested, the etiology of irritable bowel syndrome (IBS) is unknown.
More informationSmall Intestinal Bacterial Overgrowth-Symptoms, Diagnosis, and Treatment of Patients with Positive and Negative Results
Small Intestinal Bacterial Overgrowth-Symptoms, Diagnosis, and Treatment of Patients with Positive and Negative Results Martin Carr, M.D. March 3, 2018 Good evening everyone, this is Martin Carr, and I
More informationROLE OF THE GUT BACTERIA
ROLE OF THE GUT BACTERIA Our Good Bacteria In a perfect world, we would all have a proper ratio of good bacteria And what could this proper ratio do for us? The knowledge of the connections between our
More informationThe role of gut microbiome in IBS
The role of gut microbiome in IBS Chung Owyang, MD H. Marvin Pollard Professor of Internal Medicine Professor of Molecular and Integrative Physiology Chief, Division of Gastroenterology Director, Pollard
More informationSIMPOSIO Il microbiota intestinale e la sua modulazione nelle patologie dell asse intestino cervello. Microbiota e IBS.
SIMPOSIO Il microbiota intestinale e la sua modulazione nelle patologie dell asse intestino cervello Microbiota e IBS Cesare Cremon Policlinico S. Orsola Malpighi Azienda Ospedaliero - Universitaria di
More informationIl microbiota intestinale: come regola la riserva e la spesa energetica? Gerardo Nardone.
Il microbiota intestinale: come regola la riserva e la spesa energetica? Gerardo Nardone nardone@unina.it Department of Medicine and Surgery Gastroenterology Unit University Federico II, of Naples, Italy
More informationIBS The Physiologist s Perspective
IBS The Physiologist s Perspective Dr Anthony R. Hobson PhD Consultant Clinical Scientist, London The Functional Gut Clinic Reclaiming the F word The f-word functional has become a by-word for failure
More informationEffect of Lactobacillus reuteri (DSM 17938) on methane production in patients affected by functional constipation: a retrospective study
European Review for Medical and Pharmacological Sciences 2017; 21: 1702-1708 Effect of Lactobacillus reuteri (DSM 17938) on methane in patients affected by functional constipation: a retrospective study
More informationThe Bi-Phasic SIBO Protocol Module 1 Diagnosing SIBO
Dr Nirala Jacobi, BHSc, ND Author, SIBO Bi-Phasic Treatment Protocol and the SIBO Bi-Phasic Diet Medical Director, SIBOTest.com and host of TheSIBODoctor.com The Bi-Phasic SIBO Protocol Module 1 Diagnosing
More informationHompes Method. Practitioner Training Level II. Lesson Seven Part A DRG Pathogen Plus Interpretation
Hompes Method Practitioner Training Level II Lesson Seven Part A DRG Pathogen Plus Interpretation Health for the People Ltd not for reuse without expressed permission Hompes Method is a trading name of
More informationPost-Infectious Irritable Bowel Syndrome. John K. Marshall MD Division of Gastroenterology McMaster University
Post-Infectious Irritable Bowel Syndrome John K. Marshall MD Division of Gastroenterology McMaster University Pathogenesis of IBS Enck P. Nat Rev Dis Primers 2016;2:16014 Post-Infectious Irritable Bowel
More informationBloating, Flatulence, and
A 45-Year-Old Man With Recurrent Abdominal Pain, Bloating, Flatulence, and Intermittent Loose Stools Anthony J. Lembo, MD Associate Professor of Medicine Harvard Medical School Director, GI Motility Laboratory
More informationROME IV CRITERIA FOR IBS
PRACTICAL CONSIDERATIONS IN THE MANAGEMENT OF IBS BRENDA HORWITZ MD PROFESSOR OF CLINICAL MEDICINE LEWIS KATZ SCHOOL OF MEDICINE AND TEMPLE UNIVERSITY HEALTH SCIENCES CENTER OR THINGS I ALWAYS WANTED TO
More informationThe Gut Microbiota: Evidence For Gut Microbes as Contributors to Weight Gain
The Gut Microbiota: Evidence For Gut Microbes as Contributors to Weight Gain Michael T. Bailey, Ph.D. Center for Microbial Pathogenesis The Research Institute, Nationwide Children s Hospital Department
More informationEver wonder what s really happening on the inside?
For Practitioners Ever wonder what s really happening on the inside? Are your patients suffering from diarrhea, constipation, bloating, gas or indigestion? Rocky Mountain Analytical is now offering Gut-Well
More informationLaboratory report. Test: Leaky gut test. Sample material: stool. John Doe Main St 1 Anytown
1 / 5 Verisana LAB John Doe Main St 1 Anytown Surname, First name Doe, John DOB 02/13/1980 Sex male Laboratory # 20020181 Date collected 01/25/2018 Date received 02/01/2018 Report date 02/13/2018 Laboratory
More informationIBS: overview and assessment of pain outcomes and implications for inclusion criteria
IBS: overview and assessment of pain outcomes and implications for inclusion criteria William D. Chey, MD Professor of Medicine University of Michigan What is the Irritable Bowel Syndrome Symptom based
More informationLevel 2. Non Responsive Celiac Disease KEY POINTS:
Level 2 Non Responsive Celiac Disease KEY POINTS: Celiac Disease (CD) is an autoimmune condition triggered by ingestion of gluten leading to intestinal damage and a variety of clinical manifestations.
More informationFormulations and Availability 900 BILLION 5,319 HIGH POTENCY PROBIOTIC PEDIATRIC ADULT GERIATRIC PROVEN BY RESEARCH. HIGH-POTENCY. NO SHORTCUTS.
Formulations and Availability S TU D I E S PE R D I S E A S E 39 LIVER Liver Disease, Cirrhosis, Liver Failure, Hepatic Encephalopathy S TU D I E S PE R AG E G RO U P Visbiome Regular Product Code: 693-0412-01
More informationDysbiosis & Inflammation
MASTERING THE MICROBIOME: Dysbiosis & Inflammation 2017 Tom Fabian, PhD It is reasonable to propose that the composition of the microbiome and its activities are involved in most, if not all, of the biological
More informationAnnouncing SIBO Testing Updates for February 2018
Announcing SIBO Testing Updates for February 208 Dear Valued Client, In the spirit of continuous improvement and updating our testing services with the most current science and research, BioHealth is aligning
More information!Microbiology Profile, stool
LAB #: F000000-0000-0 PATIENT: Sample Patient ID: P12345 SEX: Female AGE: 37 CLIENT #: 12345 DOCTOR: Doctor's Data, Inc. 3755 Illinois Ave. St. Charles, IL 60174!Microbiology Profile, stool BACTERIOLOGY
More information2/3/2011. Adhesion of Bifidobacterium lactis HN019 to human intestinal
PROBIOTICS LEARNING THE WHY AND WHEN PROBIOTICS DEFINITION live micro-organisms organisms that are beneficial to the host organism WHO: Live organisms which, when administered in adequate amounts, confer
More informationMyalgic encephalomyelitis: A highly prevalent debilitating disease
Myalgic encephalomyelitis: A highly prevalent debilitating disease Persistent, debilitating fatigue associated with numerous physical and neurocognitive symptoms Disease severity can range from moderate
More informationDetermination of Rifaximin Treatment Period According to Lactulose Breath Test Values in Nonconstipated Irritable Bowel Syndrome Subjects
ORIGINAL ARTICLE Gastroenterology & Hepatology http://dx.doi.org/10.3346/jkms.2015.30.6.757 J Korean Med Sci 2015; 30: 757762 Determination of Rifaximin Treatment Period According to Lactulose Breath Test
More informationREFERENCE NUMBER: NH.PMN.47 EFFECTIVE DATE: 11/11
PAGE: 1 of 5 RETIRED: REVIEWED: 11/11, 12/14, 08/16, 07/17 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough
More informationIrritable Bowel Syndrome Now. George M. Logan, MD Friday, May 5, :35 4:05 PM
Irritable Bowel Syndrome Now George M. Logan, MD Friday, May 5, 2017 3:35 4:05 PM Dr. Logan indicated no potential conflict of interest to this presentation. He does not intend to discuss any unapproved/investigative
More informationRifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth
Aliment Pharmacol Ther 2005; 22: 31 35. doi: 10.1111/j.1365-2036.2005.02516.x Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth E. C. LAURITANO, M. GABRIELLI, A. LUPASCU,
More informationINTRODUCING YOUR GUT BACTERIA
INTRODUCING YOUR GUT BACTERIA Microflora Intestinal flora 1.5 kg We would die with 5 years of birth if we did not have them as we would not develop a proper immune system 1000 species and 5000 strains
More informationINTESTINAL MICROBIOTA EXAMPLES OF INDIVIDUAL ANALYSES
EXAMPLES OF INDIVIDUAL ANALYSES INTESTINAL MICROBIOTA Microbiota in the animal or human intestine has evolved together with the host. Consequently, the gastrointestinal tract could be considered a metacommunity,
More informationProbiotics in IBS. Dr. Partha Pratim Das Associate Professor Dhaka Medical college
Probiotics in IBS Dr. Partha Pratim Das Associate Professor Dhaka Medical college Definitions Probiotics: Live microorganisms that confer a health benefit on the host when administered in adequate amounts.
More informationESSENTIAL OILS & The MICROBIOME
ESSENTIAL OILS & The MICROBIOME BAHAR MAHMOUDI CONTENTS - The Human Microbiome - Benefits of the Normal Flora - Microbiome Improvement - Essential Oils 1 What is Human Microbiome Microbe: Tiny living organism,
More informationINTRODUCTION. Ujjala Ghoshal 1, Ratnakar Shukla 1, Deepakshi Srivastava 2, and Uday C Ghoshal 2
Gut and Liver, Vol. 1, No. 6, November 216, pp. 932-938 ORiginal Article Irritable Bowel Syndrome, Particularly the Constipation-Predominant Form, Involves an Increase in Methanobrevibacter smithii, Which
More informationOutcome of breath tests in adult patients with suspected small intestinal bacterial overgrowth
Gastroenterology and Hepatology From Bed to Bench. 207 RIGLD, Research Institute for Gastroenterology and Liver Diseases ORIGINAL ARTICLE Outcome of breath tests in adult patients with suspected small
More informationCorporate Medical Policy Fecal Microbiota Transplantation
Corporate Medical Policy Fecal Microbiota Transplantation File Name: Origination: Last CAP Review: Next CAP Review: Last Review: Fecal_microbiota_transplantation 7/2014 11/2017 11/2018 11/2017 Description
More informationUnderstanding probiotics and health
Understanding probiotics and health Gemma Laws MSc Student Microbiology and Immunology Department The gut microbiota The name given to the total microbial population living in our intestine Bacteria, fungi,
More informationClinically proven to quickly relieve symptoms of common gastrointestinal disorders. TERRAGASTRO - Good health starts in the gut
Clinically proven to quickly relieve symptoms of common gastrointestinal disorders GASTROINTESTINAL DISEASE Referred to as gastrointestinal diseases, they are common disorders which affect the esophagus,
More informationWelcome! Is Your Road to Good Health Paved with Good Intestines? Brenda Montrella March 5, 2013
Welcome! Is Your Road to Good Health Paved with Good Intestines? Brenda Montrella March 5, 2013 Intestinal System Small Intestinal System 1. It reabsorbs water and electrolytes and sends them back into
More informationEffect of dietary fiber on intestinal gas production and small bowel transit time in man13
ffect of dietary fiber on intestinal gas production and small bowel transit time in man13 John H. Bond,4 M.D. and Michael D. Levitt,5 M.D. ABSTRACT The influence of dietary fiber on intestinal gas production
More informationDiverticular Disease: Looking beyond fiber
Binghamton University The Open Repository @ Binghamton (The ORB) Health & Wellness Studies Faculty Scholarship Decker School of Nursing Fall 10-28-2015 Diverticular Disease: Looking beyond fiber Lina Begdache
More informationIrritable bowel syndrome (IBS) is a chronic, potentially disabling
Evidence-Based Management of Irritable Bowel Syndrome With Diarrhea Mark Pimentel, MD Irritable bowel syndrome (IBS) is a chronic, potentially disabling disorder of the gastrointestinal (GI) tract with
More informationMicrobiology - Problem Drill 21: Microbial Diseases of the Digestive System
Microbiology - Problem Drill 21: Microbial Diseases of the Digestive System No. 1 of 10 1. Which of the following organs is not part of the gastrointestinal tract (GI)? (A) Esophagus (B) Small intestine
More informationDigestive Care Advisor Training #1. Digestion 101 & H.O.P.E.
Digestive Care Advisor Training #1 & H.O.P.E. The Digestive System in Brief The Process of Digestion The human digestive system is a complex series of organs and glands that process food and excrete waste.
More informationHashimoto s Triggers Book
Chapter From Hashimoto s Triggers Book Small Intestinal Bacterial Overgrowth By Eric Osansky, DC, IFMCP, CCN, CNS www.naturalendocrinesolutions.com Table of Contents INTRODUCTION: PLEASE READ THIS FIRST
More informationCULINARY HERBS AND SPICES
CULINARY HERBS AND SPICES Using Culinary Herbs and Spices Flavour and texture are a huge issue when it comes to introducing new foods to a client Herb and spices can help make a new food seem like an old
More informationTASTE THE RAINBOW A HEALTHY GUT
TASTE THE RAINBOW A HEALTHY GUT HAVE YOU.. Taken antibiotics in the past two years? Used anti-inflammatory drugs such as aspirin or ibuprofen? Eaten processed foods? Drink sodas? Eaten foods with chemical
More informationBiomarkers of Irritable Bowel Syndrome
JNM J Neurogastroenterol Motil, Vol. 23 No. 1 January, 2017 pissn: 2093-0879 eissn: 2093-0887 https://doi.org/10.5056/jnm16135 Review Biomarkers of Irritable Bowel Syndrome Jae Hak Kim, 1 Eugenia Lin,
More informationGluten Free Alphabet Soup!
Gluten Free Alphabet Soup! Kate Scarlata, RDN, LDN Owner, For a Digestive Peace of Mind Digestive Health Nutrition Consulting Medway, MA DISCLOSERS Advisor and consultant Nestle Health Science, FODY foods,
More informationSpectrum of Diverticular Disease. Outline
Spectrum of Disease ACG Postgraduate Course January 24, 2015 Lisa Strate, MD, MPH Associate Professor of Medicine University of Washington, Seattle, WA Outline Traditional theories and updated perspectives
More informationModule Outline. 1. Microbiome overview: getting a sense of the microbiome, research, what we know
Module Outline 1. Microbiome overview: getting a sense of the microbiome, research, what we know 2. Bacteria: features, functions, communities & taxonomy 3. Other microbes: archaea, fungi, viruses, parasites
More informationMicrobiome and Small Intestinal Bacterial Overgrowth
Microbiome and Small Intestinal Bacterial Overgrowth Eamonn M M Quigley MD FRCP FACP MACG FRCPI Lynda K and David M Underwood Center for Digestive Disorders Houston Methodist Hospital equigley@houstonmethodist.org
More informationEffects of probiotics in the treatment of alcoholic hepatitis: randomized controlled multicenter study
Effects of probiotics in the treatment of alcoholic hepatitis: randomized controlled multicenter study Lactobacillus subtilis/streptococcus faecium Lactobacillus rhamnosus R0011/acidophilus R0052 Ki Tae
More informationHMP is lead by NIH but is an International Consortium.
Human Microbiome The Human Microbiome Project was one of the spin offs of the Human Genome Project. The HMP project started in 2007 with the overall goal of Characterizing the Human Microbiome and determine
More informationFood Choices and Alternative Techniques in Management of IBS: Fad Versus Evidence
Food Choices and Alternative Techniques in Management of IBS: Fad Versus Evidence Maria Vazquez Roque, MD, MSc Assistant Professor Gastroenterology and Hepatology 2010 MFMER slide-1 Objectives Gluten-free
More informationThe Human Microbiome Christine Rodriguez, Ph.D. Harvard Outreach 2012
The Human Microbiome Christine Rodriguez, Ph.D. Harvard Outreach 2012 Microbes are all over us Page 1 of 22 There are millions of microbes per square inch on your body Thousands of different species on
More informationThe number of microorganisms residing in our intestines is 10 times the number of our somatic and germ cells.
The number of microorganisms residing in our intestines is 10 times the number of our somatic and germ cells. The number of microorganisms residing in our intestines is 10 times the number of our somatic
More informationgeneral meeting 1 20 October 2016
general meeting 1 20 October 2016 introductions today s topics the human microbiome about the study the human microbiome the human microbiome human microbiota: the microorganisms that live within and on
More information4/17/2019 DISCLOSURES OBJECTIVES GI MICROBIOME & HEALTH: A REVIEW. Nancy C. Kois, MD, FCAP Contemporary Pathology Services. There are no disclosures
GI MICROBIOME & HEALTH: A REVIEW Nancy C. Kois, MD, FCAP Contemporary Pathology Services DISCLOSURES There are no disclosures OBJECTIVES Definitions: GI microbiota, GI microbiome, probiotic, prebiotic
More informationGut Microbiota and IBD. Vahedi. H M.D Associate Professor of Medicine DDRI
Gut Microbiota and IBD Vahedi. H M.D Associate Professor of Medicine DDRI 1393.3.1 2 GUT MICROBIOTA 100 Trillion Microbes - 10 times more than cells in our body Collective weight of about 1kg in human
More informationXifaxan. Xifaxan (rifaximin) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.34 Subject: Xifaxan Page: 1 of 6 Last Review Date: December 8, 2017 Xifaxan Description Xifaxan (rifaximin)
More informationDigestion. Text. What You Don t Know Can Hurt You!
Digestion Text What You Don t Know Can Hurt You! Digestive Problems Approximately 36.5 million visits annually to ambulatory care facilities due to the diseases of the digestive system Over 4 million ulcers
More informationSmall Intestinal Bacterial Overgrowth
Gastroenterology Board Review Manual Small Intestinal Bacterial Overgrowth Leonard B. Weinstock, MD INTRODUCTION Gut flora are defined as natural living organisms within the gastrointestinal (GI) tract.
More information10/4/2014. The Microbiome vs. the Gastroenterologist. Human Microbiome. Microbiome and Host Physiology: A Delicate Balance
The Microbiome vs. the Gastroenterologist John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University Human Microbiome Mouth Finlay BB. Scientific American 2010;302:56-63 Microbiome
More informationModule Four: The GI System Module Five: The Gut Microbiome. The GI System. LLiana Shanti, CN
Module Four: The GI System Module Five: The Gut Microbiome The GI System LLiana Shanti, CN www.healthmasteryinstitute.com Review Review Review The Gut Hippocrates has been quoted as saying death sits in
More informationPROBIOTICS: WHO S WHO AND WHAT S WHAT IN THE GUT PROBIOTICS: WHAT ARE THEY, AND HOW DO THEY WORK? Karen Jensen, (Retired ND)
PROBIOTICS: WHO S WHO AND WHAT S WHAT IN THE GUT Karen Jensen, (Retired ND) Today many people are aware of the benefits of maintaining a healthy gut. As a result, probiotic use is becoming ever more popular.
More informationIJBPAS, December, 2014, 3(12): SMALL INTESTINE BACTERIAL OVERGROWTH IN IRANIAN IRRITABLE BOWEL SYNDROME PATIENTS
: 3041-3050 ISSN: 2277 4998 SMALL INTESTINE BACTERIAL OVERGROWTH IN IRANIAN IRRITABLE BOWEL SYNDROME PATIENTS RAHMATOLLAH RAFIEI 1, MITRA SHAVAKHI 2, LOOTFOLLAH FOULADI 3, MOHAMMAD ARASH RAMEZANI 4 AND
More informationCASE STUDY: ULCERATIVE COLITIS. Sammi Montag Dietetic Intern
CASE STUDY: ULCERATIVE COLITIS Sammi Montag Dietetic Intern 2013-2014 PATIENT (CK) INTRODUCTION 26 year old female Chief complaint: bloody diarrhea and abdominal pain Admitting diagnosis: Ulcerative colitis
More informationFeatured Topic: Get Digestive Relief (and more) with Probiotics (4 slides)
Featured Topic: Get Digestive Relief (and more) with Probiotics (4 slides) 3 things you need to know about probiotics Probiotics are helpful bacteria Probiotics prevent disease, they don t cause it (bad
More informationProton pump inhibitors (PPIs) are potent drugs producing
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2010;8:504 508 Increased Incidence of Small Intestinal Bacterial Overgrowth During Proton Pump Inhibitor Therapy LUCIO LOMBARDO,* MONICA FOTI,* OLGA RUGGIA,* and
More informationHompes Method. Practitioner Training Level II. Lesson Eight Part 1C SIBO Protocols
Hompes Method Practitioner Training Level II Lesson Eight Part 1C SIBO Protocols Health for the People Ltd not for reuse without expressed permission Hompes Method is a trading name of Health For The People
More informationProbiotics: Their Role in Medicine Today. Objectives. Probiotics: What Are They? 11/3/2017
Probiotics: Their Role in Medicine Today Viki Barr Pharm.D., BCPS AQ ID Assistant Professor, Pharmacy Practice Rosalind Franklin University of Medicine and Science Clinical Pharmacist, Infectious Diseases
More informationT H E B E T T E R H E A L T H N E W S
Dr. Paul G. Varnas & WholeHealthAmerica.com present V O L U M E 1 3, I S S U E 4 T H E B E T T E R H E A L T H N E W S A P R I L, 2 0 1 6 M O R E P R O B L E M S W I T H P R O T O N P U M P I N H I B I
More informationIrritable bowel syndrome (IBS) is a chronic relapsing and
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:1279 1286 Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: Systematic Review and Meta-analysis ALEXANDER C. FORD,* BRENNAN M. R. SPIEGEL,
More informationMicrobial Flora of Normal Human Body Dr. Kaya Süer. Near East University Medical Faculty Infectious Diseases and Clinical Microbiology
Microbial Flora of Normal Human Body Dr. Kaya Süer Near East University Medical Faculty Infectious Diseases and Clinical Microbiology Normal Microbial Flora Skin Conjunctivae Oral Cavity Upper respiratory
More informationStool Testing for the Microbiome - Ready for Primetime?
Stool Testing for the Microbiome - Ready for Primetime? Gillian M. Barlow, PhD Project Scientist, Medically Associated Science and Technology (MAST) Program Cedars-Sinai Medical Center Take Charge of
More information1. Digestion of foods and absorption of nutrients takes place in stomach and small bowel in only 2-3 h.
1. Digestion of foods and absorption of nutrients takes place in stomach and small bowel in only 2-3 h. 2. The waste is then stored for 2 days in the large bowel. 3. Do modern humans need a large bowel?
More informationDiarrhea. Donald P. Kotler, MD
Diarrhea Donald P. Kotler, MD 1 1 2 2 3 3 Intestinal mucosa Large surface area Stable ionic microenvironment Epithelial cell turnover Epithelial cell maturation Structural and functional adaptations Epithelial
More informationDiarrhea. Donald P. Kotler, MD
Diarrhea Donald P. Kotler, MD 1 1 Intestinal mucosa Large surface area Stable ionic microenvironment Epithelial cell turnover Epithelial cell maturation Structural and functional adaptations Epithelial
More informationAzienda Ospedaliera S. Camillo Forlanini. Unità Operativa di Gastroenterologia. Moscow June Cosimo Prantera
/ Azienda Ospedaliera S. Camillo Forlanini Unità Operativa di Gastroenterologia Moscow June 2006 Cosimo Prantera ANTIBIOTICS AND BACTERIAL SPECIES Metronidazole Bacteroides - Clostridia Ciprofloxacin Escherichia
More informationJointly sponsored by Purdue University College of Pharmacy and the Gi Health Foundation. This activity is supported by Salix Pharmaceuticals.
Accredited by Jointly sponsored by Purdue University College of Pharmacy and the Gi Health Foundation. This activity is supported by Salix Pharmaceuticals. Mark Pimentel, MD Cedars-Sinai Medical Center
More informationCampylobacter jejuni
U.S. Food & Drug Administration Center for Food Safety & Applied Nutrition Foodborne Pathogenic Microorganisms and Natural Toxins Handbook Campylobacter jejuni 1. Name of the Organism: Campylobacter jejuni
More informationNon-Invasive Assessment of Intestinal Function
Overview Non-Invasive Assessment of Intestinal Function Introduction This paper will demonstrate that the 13 C-sucrose breath test ( 13 C-SBT) determines the health and function of the small intestine.
More informationWEBINAR Microbial Metabolism Associated with Health. 12 April 2018; CET
WEBINAR Microbial Metabolism Associated with Health 12 April 2018; 15.00-16.30 CET PROGRAMME Brief Introduction of Both Organisations and Scientific Background Dr Bettina Schelkle (ILSI Europe, BE) Dr
More informationWhat GI Physicians Need to Know About Probiotics
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/gi-insights/what-gi-physicians-need-to-know-about-probiotics/3844/
More informationXifaxan, Lotronex and Viberzi Prior Authorization and Quantity Limit Program Summary
Xifaxan, Lotronex and Viberzi Prior Authorization and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1,2 Lotronex (alosetron) a Indication For women with severe diarrheapredominant irritable
More informationThe prebiotic potential of Australian honeys. Nural Cokcetin, Shona Blair & Patricia Conway The University of New South Wales Sydney, Australia
The prebiotic potential of Australian honeys Nural Cokcetin, Shona Blair & Patricia Conway The University of New South Wales Sydney, Australia Introduction Gut bacteria significantly impacts host health
More information